TransCode Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | -$0.58 | -$0.58 | -$0.58 |
| Q2 2024 | 1 | -$0.16 | -$0.16 | -$0.16 |
| Q3 2024 | 1 | -$0.30 | -$0.30 | -$0.30 |
TransCode Therapeutics, Inc. Earnings Date And Information
TransCode Therapeutics, Inc. last posted its earnings results on Wednesday, August 14th, 2024. The company reported $-0.74 earnings per share for the quarter, missing analysts' consensus estimates of $-0.58 by $0.16. The company had revenue of 0 for the quarter and had revenue of 0 for the year. TransCode Therapeutics, Inc. has generated $-104 earnings per share over the last year ($-103.61 diluted earnings per share) and currently has a price-to-earnings ratio of -0.38. TransCode Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Friday, March 28th, 2025 based on prior year's report dates.
TransCode Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/14/2024 | Q3 2024 | -$0.16 | $300,000 | $0 | ||
| 08/14/2024 | Q2 2024 | -$0.58 | -$0.74 | -0.16 | $0 | $0 |
| 05/15/2024 | Q1 2024 | -$0.70 | -$0.65 | 0.05 | $0 | |
| 04/01/2024 | Q4 2023 | -$22.83 | $753,146 | |||
| 09/29/2023 | Q3 2023 | -$67.95 | $0 | |||
| 08/14/2023 | Q2 2023 | -$135.60 | -$135.68 | -0.08 | $0 | |
| 05/15/2023 | Q1 2023 | -$267.34 | $0 | |||
| 03/31/2023 | Q4 2022 | -$304.00 | -$1,134.84 | -830.84 | $0 | |
| 11/14/2022 | Q3 2022 | -$320.00 | -$264.45 | 55.55 | $0 | |
| 08/15/2022 | Q2 2022 | -$0.30 | -$289.70 | -289.4 | $0 | |
| 05/16/2022 | Q1 2022 | -$216.41 | $0 | |||
| 03/31/2022 | Q4 2021 | -$0.25 | -$552.15 | -551.9 | $0 | |
| 11/15/2021 | Q3 2021 | -$164.25 | $0 | |||
| 08/23/2021 | Q2 2021 | $589.73 | $0 | |||
| 03/31/2021 | Q1 2021 | -$278.07 | $0 | |||
| 12/31/2020 | Q4 2020 | -$100.46 | $0 | |||
| 09/29/2020 | Q3 2020 | -$172.19 | $0 | |||
| 06/29/2020 | Q2 2020 | -$15.94 | $0 | |||
| 03/31/2020 | Q1 2020 | -$6.53 | $0 | |||
| 12/30/2019 | Q4 2019 | -$30.53 | $0 |
TransCode Therapeutics, Inc. Earnings: Frequently Asked Questions
-
When is TransCode Therapeutics, Inc.'s earnings date?
TransCode Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Friday, March 28th, 2025 based off last year's report dates.
-
How can I listen to TransCode Therapeutics, Inc.'s earnings conference call?
The conference call for TransCode Therapeutics, Inc.'s latest earnings report can be listened to online.
-
How can I read TransCode Therapeutics, Inc.'s conference call transcript?
The conference call transcript for TransCode Therapeutics, Inc.'s latest earnings report can be read online.
-
How much profit does TransCode Therapeutics, Inc. generate each year?
TransCode Therapeutics, Inc. (:RNAZ) has a recorded net income of $0. TransCode Therapeutics, Inc. has generated $-103.61 earnings per share over the last four quarters.
-
What is TransCode Therapeutics, Inc.'s price-to-earnings ratio?
TransCode Therapeutics, Inc. (:RNAZ) has a price-to-earnings ratio of -0.38 and price/earnings-to-growth ratio is 0.
